BlackRock Amends Cardlytics Stake, Signals Continued Passive Investment
Ticker: CDLX · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1666071
| Field | Detail |
|---|---|
| Company | Cardlytics, Inc. (CDLX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns Cardlytics stock, showing they're in it for the long haul.**
AI Summary
BlackRock, Inc. filed an amended SC 13G/A on January 26, 2024, indicating its ownership of Cardlytics, Inc. common stock as of December 31, 2023. This filing, Amendment No. 3, updates previous disclosures about BlackRock's passive investment in Cardlytics. This matters to investors because BlackRock is a major institutional investor, and its continued, albeit passive, stake suggests a level of confidence in Cardlytics' long-term prospects, even if the exact percentage of ownership isn't detailed in this snippet.
Why It Matters
This filing shows that BlackRock, a massive asset manager, continues to hold a significant, passive stake in Cardlytics, which can be seen as a vote of confidence in the company's future.
Risk Assessment
Risk Level: low — This is a routine amendment by a large institutional investor, indicating passive ownership and not a change in strategy or a significant new risk.
Analyst Insight
Investors should view this as a routine update from a major institutional holder, confirming BlackRock's continued, passive interest in Cardlytics. It doesn't signal an immediate buy or sell, but rather a stable institutional presence.
Key Numbers
- 14161W105 — CUSIP Number (identifies Cardlytics, Inc. Common Stock)
- 3 — Amendment Number (indicates this is the third amendment to BlackRock's Schedule 13G filing for Cardlytics)
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- Cardlytics, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring this filing
- January 26, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- BlackRock will maintain a passive investment in Cardlytics, Inc. for the foreseeable future. (BlackRock, Inc.) — high confidence, target: December 31, 2024
- Cardlytics, Inc. will continue to be a publicly traded company. (Cardlytics, Inc.) — high confidence, target: December 31, 2025
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing under the Securities Exchange Act of 1934, specifically Amendment No. 3.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., identified by CIK 0001364742.
What company's securities are being reported on?
The securities of Cardlytics, Inc. (CIK 0001666071) are being reported on, specifically their Common Stock.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires filing of this statement was December 31, 2023.
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding Cardlytics, Inc. (CDLX).